Orthopedics devices maker ConforMIS launched a $68 million funding round that will close at the end of this month.
ConforMIS is offering equity, securities and options with no minimum investor, according to regulatory filings.
The privately held custom joint implant maker is on a roll, having raised $89 million in a Series E funding round earlier this year, bringing its fund-raising collections to about $140 million since 2009.
The company has a broader vision for competing in the market for other joint replacements, some as soon as this year, CEO Philip Lang told MassDevice.com in a podcast interview in February, shortly after the company won FDA 510(k) clearance for its iTotal CR customized knee replacement system.
"This is not just a knee company. It’s really a platform company," Lang told us. "We have been issued patents for hips, for shoulder, ankle, spine, and there’s clearly the opportunity to do what is so disruptive today in the knee joint, and take it into other joints."
Unlike standard implants, iTotal CR devices are based on an individual’s CT scans and tailored for their knee bones using computer-aided design.
Standard implants come in 6 or 7 different sizes, meaning that surgeons must measure a patient’s bones after an incision to select the best fit. The ConforMIS total knee implants, designed for patients with knee damage from conditions such as osteoarthritis, are individually built using three-dimensional CT scans of the patient’s knee.